Outcomes in elderly patients admitted to the intensive care unit with solid tumors

Édouard Auclin(Centre Hospitalier de l’Université de Montréal), Nadia Aïssaoui(Université Paris Cité), Julien Taı̈eb(Hôpital Européen Georges-Pompidou), Constance Thibault(Hôpital Européen Georges-Pompidou), Jean‐Luc Diehl, Stéphane Oudard(Assistance Publique – Hôpitaux de Paris), Alexandra Monnier(Délégation Paris 5), Baptiste Abbar(Inserm), Anaïs Charles‐Nelson(Inserm), Emmanuel Guérot(Délégation Paris 5), Sandrine Katsahian(Inserm), Jean-Yves Fagon(Royal Statistical Society), Caroline Hauw‐Berlemont(Assistance Publique – Hôpitaux de Paris)
Annals of Intensive Care
January 1, 2017
10.1186/s13613-017-0250-0
Cited by 69

Related Papers

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2017|1.4k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
|The Lancet Oncology|2016|914
Presence of B Cells in Tertiary Lymphoid Structures Is Associated with a Protective Immunity in Patients with Lung Cancer
|American Journal of Respiratory and Critical Care Medicine|2014|806
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|645